A detailed history of Antipodean Advisors LLC transactions in Atara Biotherapeutics, Inc. stock. As of the latest transaction made, Antipodean Advisors LLC holds 1,000,000 shares of ATRA stock, worth $12 Million. This represents 8.12% of its overall portfolio holdings.

Number of Shares
1,000,000
Previous 1,000,000 -0.0%
Holding current value
$12 Million
Previous $1.61 Million 8.07%
% of portfolio
8.12%
Previous 12.42%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$14.7 - $19.89 $735,000 - $994,500
-50,000 Reduced 4.76%
1,000,000 $15.8 Million
Q3 2021

Nov 15, 2021

BUY
$11.99 - $17.9 $599,500 - $894,999
50,000 Added 5.0%
1,050,000 $18.8 Million
Q3 2020

Nov 16, 2020

BUY
$11.92 - $15.87 $2.38 Million - $3.17 Million
200,000 Added 25.0%
1,000,000 $13 Million
Q2 2020

Aug 14, 2020

BUY
$7.53 - $14.93 $4.36 Million - $8.64 Million
579,000 Added 261.99%
800,000 $11.7 Million
Q1 2020

May 15, 2020

BUY
$5.69 - $17.78 $1.26 Million - $3.93 Million
221,000 New
221,000 $1.88 Million

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $1.13B
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track This Portfolio

Track Antipodean Advisors LLC Portfolio

Follow Antipodean Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Antipodean Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Antipodean Advisors LLC with notifications on news.